Microbial Exosome Services
OverviewServiceSamplesAdvantagesCase StudyFAQs
Overview
Service Overview
At Creative BioMart Microbe, we provide comprehensive microbial extracellular vesicle (EV) solutions spanning isolation, purification, characterization, functional validation, and application-grade manufacturing. Microbial EVs—including bacterial outer membrane vesicles (OMVs), membrane vesicles (MVs) from Gram-positive species, and fungal exosomes—are emerging as powerful tools for vaccine development, targeted drug delivery, host-microbe interaction research, and microbiome diagnostics.
Our platform supports both wild-type and engineered microbial strains, offering end-to-end services from strain cultivation and fermentation optimization to GMP-compatible process development. Whether you require native vesicles for mechanistic studies or engineered vesicles loaded with therapeutic cargoes, our integrated workflow ensures batch-to-batch consistency, rigorous quality control, and scalable production.
Figure 1. Schematic overview of Creative BioMart Microbe's Microbial Exosome Services, illustrating the integrated service ecosystem.
Supported Microbial Systems
Our service is validated across the most widely used laboratory and industrial microbial backgrounds. Additional species and engineered chassis are available upon request.
- Gram-negative bacteria: E. coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Salmonella spp., Neisseria spp., and other species upon request
- Gram-positive bacteria: Bacillus subtilis, Staphylococcus aureus, Lactobacillus spp., and other species upon request
- Fungi & Yeast: Candida albicans, Saccharomyces cerevisiae, and other species upon request
- Engineered strains: Custom knockout or knock-in strains for enhanced vesicle secretion, reduced toxicity, or surface antigen display
Creative BioMart Microbe offers end-to-end microbial extracellular vesicle services, from strain engineering to validated batch delivery. Contact us for a custom quote.
Our Service
Service Workflow
Service Details
Exosome-Producing Strain Engineering & Fermentation Optimization
We engineer microbial chassis to maximize extracellular vesicle yield and functionality while minimizing endotoxin burden. Our services include wild-type strain screening, species identification, and fermentation parameter optimization (medium composition, pH, dissolved oxygen, temperature, and agitation). For advanced applications, we perform targeted genome editing—such as msbB knockout to reduce LPS toxicity or heterologous antigen knock-in for vaccine development—to generate high-performing, application-ready vesicle producers.
Exosome Isolation & Purification Services
We isolate and purify microbial EVs from culture supernatants or fermentation broths using orthogonal separation strategies tailored to vesicle type and downstream application. Our protocols effectively deplete free proteins, lipopolysaccharides (LPS), cell debris, and intact cells while preserving vesicle structural integrity and biological activity.
Exosome Characterization & Quality Analytics
We deliver comprehensive physicochemical and biochemical characterization packages that meet both publication and pre-IND standards. Our analytics distinguish microbial EVs from contaminating membrane fragments and quantify microbial-specific markers such as outer membrane proteins (OMPs), lipopolysaccharides (LPS), and lipoteichoic acids (LTA).
Exosome Functional Validation & Mechanism of Action Studies
We validate the biological activity of microbial EVs through standardized in vitro and in vivo assays. Our functional studies assess cellular uptake efficiency, immunomodulatory potency, and therapeutic mechanism of action to support translational research and regulatory filings.
Exosome Engineering & Drug Loading Services
We transform native microbial vesicles into targeted delivery vehicles through surface modification and cargo loading. Our engineering platform supports both genetic (pre-secretion) and post-isolation chemical modification strategies, enabling precise control over vesicle tropism and payload release kinetics.
Application-Grade Exosome Manufacturing
We manufacture microbial EVs at defined quality tiers to match your regulatory and application requirements. Our tiered manufacturing framework ensures that material destined for in vitro research, food-grade formulations, cosmetic actives, or preclinical evaluation is produced under appropriately controlled conditions with full traceability.
Exosome Formulation Development & Stability Solutions
We develop stable, storage-ready formulations that maintain vesicle integrity and bioactivity across the product lifecycle. Our stability programs define optimal buffer systems, cryoprotectants, and container-closure configurations to support long-term inventory, global shipping, and diverse administration routes.
Service Specifications
Isolation Capability
- Input material: Bacterial or fungal culture supernatant, fermentation broth, or live culture (with provided protocol)
- Processing volume: 50 mL–5 L per batch; multi-liter scale-up available upon consultation
Yield & Quality
- Yield: 109–1012 particles / L culture (species and strain dependent)
- Purity: ≥ 85% by particle-to-protein ratio (NTA + BCA)
- Endotoxin (optimized): < 0.1 EU/mL for low-endotoxin protocols
- Size distribution: 30–300 nm; polydispersity index (PDI) < 0.3 where specified
Turnaround Time
| Project Type |
Timeline |
| Basic isolation & concentration |
1–2 weeks |
| Isolation + purification + characterization |
2–3 weeks |
| Full package (isolation, purification, characterization, functional assay) |
3–5 weeks |
| Engineered strain construction + vesicle production |
4–6 weeks |
| Large-scale manufacturing & formulation |
6–10 weeks |
Timeline may vary based on microbial species, strain engineering complexity, and project scale. Custom quotes available for expedited projects.
Deliverables
- Purified vesicle sample (frozen at –80°C or lyophilized, as requested)
- Particle size distribution report (NTA / DLS)
- TEM / Cryo-TEM micrographs
- Concentration and total particle count data
- Protein and nucleic acid quantitation (BCA, NanoDrop, or LC-MS/MS as applicable)
- Endotoxin test report (LAL assay, where applicable)
- Comprehensive QC report (PDF) with methodology and raw data
Quality Control
- Particle size consistency verification (NTA, n ≥ 3 technical replicates)
- Sterility testing (bacterial and fungal culture)
- Protein contamination assessment (BCA or Bradford)
- Endotoxin quantitation (LAL chromogenic or turbidimetric assay)
- Batch-to-batch reproducibility verification (≥ 2 independent batches for manufacturing projects)
Sample Requirements
| Required Information |
Optional Information |
Not Accepted |
- Microbial species / strain name and genotype
- Culture conditions (medium formulation, temperature, incubation time, aeration)
- Target application (research, functional assay, vaccine, drug delivery, etc.)
- Desired vesicle type if known (OMVs, MVs, fungal exosomes)
|
- Special handling requirements (anaerobic, biosafety level, etc.)
- Low-endotoxin or LPS-detoxification preference
- Downstream assay compatibility needs (cell culture, in vivo, proteomics)
- Engineering targets (knockout, knock-in, or surface modification requests)
|
- Heavily contaminated or unidentified cultures without prior consultation
- Unknown or uncharacterized strains lacking growth protocol documentation
- Biosafety Level 3 (BSL-3) or higher pathogens without institutional biosafety approval
|
Sample Submission Guidelines
- Culture supernatant (preferred): ≥ 50 mL, shipped on ice within 24 h of harvest
- Live culture: Provide detailed cultivation protocol; we perform in-house expansion and vesicle harvest
- Storage & shipping: Supernatants should be cleared of intact cells by low-speed centrifugation before shipment; avoid repeated freeze-thaw cycles
Our Advantages
- Broad Microbial Coverage: Proven protocols across Gram-negative, Gram-positive, fungal, and engineered bacterial strains, ensuring platform flexibility for diverse research and industrial needs.
- High-Yield Production Platform: Optimized fermentation and strain engineering strategies achieving vesicle yields up to 1012 particles/L and 2–10× improvement over baseline wild-type secretion.
- Advanced Endotoxin Control: Optional LPS detoxification and genetic attenuation (e.g., msbB knockout) delivering endotoxin levels below 0.1 EU/mL, suitable for immunological and in vivo applications.
- Scalable, Tiered Manufacturing: From milliliter-scale research batches to multi-liter application-grade production under research, food, cosmetic, or GMP-aligned standards.
- Engineering-to-Formulation Continuity: Seamless transition from strain construction and vesicle isolation to surface modification, cargo loading, and stable lyophilized formulation—reducing vendor fragmentation.
- Rapid Turnaround with Milestone Transparency: Standard isolation projects delivered in as fast as 1–2 weeks, with stage-gate reporting at cultivation, harvest, purification, and QC milestones.
Case Study
Case Study 1: CRISPR/Cas9-Mediated msbB Knockout in E. coli for Engineered Low-Endotoxin OMV Development
Research mapping the bacterial extracellular vesicle field identifies E. coli as the dominant chassis for OMV preparation, accounting for 22 % of all reported BEV experiments. Proteomic surveys of wild-type E. coli OMVs reveal a characteristic cargo signature dominated by outer membrane protein A (OmpA) alongside virulence-associated factors such as Shiga toxin 2 subunit A (Stx2a) and hexa-acylated lipopolysaccharide (LPS). Using λRed-assisted CRISPR/Cas9 recombineering with ~400 bp homology arms, researchers achieved a marker-free scarless knockout of the msbB lipid-A biosynthesis gene in E. coli. The engineered strain produced OMVs with penta-acylated lipid A, exhibiting significantly attenuated endotoxin activity compared to wild-type while retaining structural integrity, yield, and key immunogenic envelope proteins. Functional validation in macrophage models confirmed that msbB-knockout OMVs retained potent immunogenicity yet displayed markedly reduced cytotoxicity. This case illustrates how precise scarless knockout of a single LPS-modifying gene enables rapid engineering of safer, acellular vaccine vectors from the most widely utilized OMV chassis.
Figure 2. Treemap analysis of BEV-enriched (purple) and BEV-depleted (blue) proteins identified in E. coli-derived OMVs across laboratory studies. (De Langhe, et al. 2024)
Case Study 2:CRISPR/Cas9-Mediated Knockout of msbB in E. coli BL21 for Low-Endotoxin OMV Nanorobot Development
Research in PNAS demonstrates CRISPR/Cas9-mediated knockout of the msbB gene in E. coli BL21 using λRed-assisted recombineering with ~400 bp homology arms. The marker-free scarless deletion yielded penta-acylated lipid A OMVs with significantly attenuated endotoxin activity while preserving yield and morphology. The engineered chassis supported surface-displayed CPP and siRNA-loaded, urease-powered nanorobots for bladder tumor therapy. This case illustrates how single-gene scarless knockout rapidly generates a safe, high-performance OMV platform for advanced drug delivery.
Figure 3. Schematic of the fabrication process of OMV-siR robots with surface-bioengineered CPP capable of tumor-targeted binding and penetration. (Tang, et al. 2024)
FAQs
Q: What is the difference between bacterial OMVs, MVs, and fungal exosomes?
A: Outer membrane vesicles (OMVs) bud from the outer membrane of Gram-negative bacteria and typically range from 20–300 nm. Membrane vesicles (MVs) from Gram-positive bacteria originate from the cytoplasmic membrane or cell wall, often under stress conditions. Fungal exosomes are secreted via multivesicular body pathways and share biogenesis mechanisms with mammalian exosomes. Our platform isolates and characterizes all three types with species-optimized protocols.
Q: Can you reduce or eliminate endotoxin (LPS) from bacterial vesicles?
A: Yes. We offer both biochemical LPS detoxification and genetic attenuation strategies. For example, we can engineer msbB knockout strains that produce lipid A with reduced immunostimulatory activity, or apply detergent-based and affinity-based removal to achieve endotoxin levels below 0.1 EU/mL for sensitive in vivo and cell-based applications.
Q: What microbial species do you support for vesicle isolation?
A: We routinely handle Gram-negative species (E. coli, Pseudomonas, Salmonella, Klebsiella, Neisseria), Gram-positive species (Bacillus, Staphylococcus, Lactobacillus), and fungi/yeast (Candida, Saccharomyces). Custom species are accepted following a brief feasibility assessment of culture conditions and vesicle yield potential.
Q: Do you support large-scale manufacturing for preclinical or commercial supply?
A: Yes. Our application-grade manufacturing tier supports multi-liter fermentation and purification under research, food-grade, cosmetic-grade, or GMP-aligned conditions. We provide batch-to-batch consistency validation, full traceability documentation, and stability data to support preclinical development and ingredient commercialization.
Q: How are vesicles loaded with therapeutic cargo?
A: We employ multiple loading strategies depending on cargo type: electroporation for nucleic acids (siRNA, mRNA), passive incubation or thermal shock for small molecules, and genetic fusion for recombinant proteins displayed on the vesicle surface. Loading efficiency and release kinetics are quantified as part of the standard deliverables package.
Q: What is the typical turnaround time for a standard isolation project?
A: A standard isolation and concentration project is typically delivered in 1–2 weeks. Projects requiring purification, full characterization, or functional validation range from 2–5 weeks. Engineered strain construction and large-scale manufacturing projects require 4–10 weeks depending on complexity.
References:
- De Langhe, N., et al. (2024). Mapping bacterial extracellular vesicle research: insights, best practices and knowledge gaps. Nature communications, 15(1), 9410.
- Tang, S., et al. (2024). Bacterial outer membrane vesicle nanorobot. Proceedings of the National Academy of Sciences, 121(30), e2403460121.
